Application of 68Ga-labeled ACE2 Targeting Probe PET/CT Imaging in Tracing ACE2 Expression and Diagnosis of Lung Cancer
试验速览
- 阶段
- 早期 1 期
- 状态
- 招募中
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- standardized uptake value (SUV)
研究概览
简要总结
In the past three years, as the key protein suggested to be involved in host cell entry of SARS-CoV-2, studies of ACE2 aroused people's attention again. Tracking the expression of ACE2 in vivo is crucial to further understanding of COVID-19, dynamically monitoring the effect of antiviral therapy and the development of related vaccines. It is also expected to further conduct in-depth research on the physiological effects of ACE2 and RAAS, and the mechanism of ACEI/ARB (32). With the development of both molecular imaging agents and related equipment, several ACE2-targeting PET imaging agents have been investigated based on different strategies while some of them were tested in clinical trials. The aim of this study was to intercept key ACE2-binding sites from coronavirus RBD and test their potential as ACE2-targeting PET agents.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •the ability to provide informed written consent
- •a medical history without any ACE2-related comorbidities
排除标准
- •liver and renal function dysfunction,
- •pregnancy or current lactation
研究组 & 干预措施
68Ga-A3
Within 1 week, each participant underwent PET/CT scan after intravenous administration of 68Ga-A3
干预措施: 68Ga-A3 (Drug)
结局指标
主要结局
standardized uptake value (SUV)
时间窗: through study completion, an average of 1 year
comparing the SUVmean of different organs or lesions
次要结局
- Diagnostic performance(through study completion, an average of 1 year)